<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prognosis of patients relapsing after stem cell transplantation (SCT) is poor if no further treatment is given </plain></SENT>
<SENT sid="1" pm="."><plain>A second SCT is a limited option in these high-risk patients </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively analyzed the outcomes of second SCT in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> after a first SCT </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-five of 30 patients received second allogeneic SCT </plain></SENT>
<SENT sid="4" pm="."><plain>Variables related to survival were disease status before second allogeneic SCT and time interval between transplants more than 1 year (P&lt;.01 and P&lt;.02 in multivariate analysis) </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment-related mortality was 33% with no impact of the conditioning regimen on overall survival </plain></SENT>
<SENT sid="6" pm="."><plain>Second allogeneic SCT in selected patients may be an option in this group with a poor outcome </plain></SENT>
</text></document>